Sleeping Beauty mRNA-LNP enables stable rAAV transgene expression in mouse and NHP hepatocytes and improves vector potency
Philip M Zakas,Sharon C Cunningham,Ann Doherty,Eva B van Dijk,Raed Ibraheim,Stephanie Yu,Befikadu D Mekonnen,Brendan Lang,Elizabeth J English,Gang Sun,Miles C Duncan,Matthew S Benczkowski,Robert C Altshuler,Malvenderjit Jagjit Singh,Emily S Kibbler,Gulen Y Tonga,Zi Jun Wang,Z Jane Wang,Guangde Li,Ding An,James B Rottman,Yashvi Bhavsar,Cormac Purcell,Rachit Jain,Ryan Alberry,Nathaniel Roquet,Yanfang Fu,Robert J Citorik,Jacob R Rubens,Michael C Holmes,Cecilia Cotta-Ramusino,William Querbes,Ian E Alexander,William E Salomon
DOI: https://doi.org/10.1016/j.ymthe.2024.06.021
2024-10-02
Abstract:Recombinant adeno-associated virus (rAAV) vector gene delivery systems have demonstrated great promise in clinical trials but continue to face durability and dose-related challenges. Unlike rAAV gene therapy, integrating gene addition approaches can provide curative expression in mitotically active cells and pediatric populations. We explored a novel in vivo delivery approach based on an engineered transposase, Sleeping Beauty (SB100X), delivered as an mRNA within a lipid nanoparticle (LNP), in combination with an rAAV-delivered transposable transgene. This combinatorial approach achieved correction of ornithine transcarbamylase deficiency in the neonatal Spfash mouse model following a single delivery to dividing hepatocytes in the newborn liver. Correction remained stable into adulthood, while a conventional rAAV approach resulted in a return to the disease state. In non-human primates, integration by transposition, mediated by this technology, improved gene expression 10-fold over conventional rAAV-mediated gene transfer while requiring 5-fold less vector. Additionally, integration site analysis confirmed a random profile while specifically targeting TA dinucleotides across the genome. Together, these findings demonstrate that transposable elements can improve rAAV-delivered therapies by lowering the vector dose requirement and associated toxicity while expanding target cell types.